Cesca Therapeutics Company Profile (NASDAQ:KOOL)

About Cesca Therapeutics (NASDAQ:KOOL)

Cesca Therapeutics logoCesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KOOL
  • CUSIP: N/A
  • Web: www.cescatherapeutics.com
Capitalization:
  • Market Cap: $30.85 million
  • Outstanding Shares: 9,886,000
Average Prices:
  • 50 Day Moving Avg: $3.12
  • 200 Day Moving Avg: $3.05
  • 52 Week Range: $2.41 - $7.39
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.64
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $13.58 million
  • Price / Sales: 2.27
  • Book Value: $3.41 per share
  • Price / Book: 0.92
Profitability:
  • EBIDTA: ($7,620,000.00)
  • Net Margins: -297.49%
  • Return on Equity: -37.44%
  • Return on Assets: -25.80%
Debt:
  • Current Ratio: 3.09%
  • Quick Ratio: 2.24%
Misc:
  • Average Volume: 89,365 shs.
  • Beta: -0.66
  • Short Ratio: 2.37
 

Frequently Asked Questions for Cesca Therapeutics (NASDAQ:KOOL)

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) announced its quarterly earnings data on Tuesday, February, 16th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The business earned $3.29 million during the quarter, compared to analysts' expectations of $4.32 million. Cesca Therapeutics had a negative return on equity of 37.44% and a negative net margin of 297.49%. View Cesca Therapeutics' Earnings History.

Who are some of Cesca Therapeutics' key competitors?

Who owns Cesca Therapeutics stock?

Cesca Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.62%). Company insiders that own Cesca Therapeutics stock include (Hong Kong) Ltd Boyalife, Kenneth Harris and Matthew T Plavan. View Institutional Ownership Trends for Cesca Therapeutics.

Who bought Cesca Therapeutics stock? Who is buying Cesca Therapeutics stock?

Cesca Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Cesca Therapeutics.

How do I buy Cesca Therapeutics stock?

Shares of Cesca Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cesca Therapeutics stock cost?

One share of Cesca Therapeutics stock can currently be purchased for approximately $3.12.

Analyst Ratings

Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Maxim GroupReiterated RatingHoldLowView Rating Details
9/21/2015HC WainwrightUpgradeNeutral -> Buy$2.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)
Earnings by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Earnings History by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2017Q2 2017($0.35)$4.01 millionViewN/AView Earnings Details
11/17/2016Q1 2017($0.34)$3.77 millionViewN/AView Earnings Details
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details
9/17/2015Q415($0.11)($0.06)$4.08 million$3.70 millionViewListenView Earnings Details
6/23/2015Q315($0.08)($0.12)$4.69 million$4.04 millionViewListenView Earnings Details
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details
5/15/2014Q3 2014($0.05)($0.07)$4.04 millionViewN/AView Earnings Details
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details
11/14/2013Q1($0.14)ViewListenView Earnings Details
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
Current Year EPS Consensus Estimate: $-4.5200 EPS
Next Year EPS Consensus Estimate: $-1.1800 EPS

Dividends

Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cesca Therapeutics (NASDAQ:KOOL)
Insider Ownership Percentage: 26.60%
Institutional Ownership Percentage: 2.30%
Insider Trades by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Institutional Ownership by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Insider Trades by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/26/2016(Hong Kong) Ltd BoyalifeMajor ShareholderBuy6,102,942$2.52$15,379,413.84View SEC Filing  
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.80View SEC Filing  
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.80View SEC Filing  
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.00View SEC Filing  
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.00View SEC Filing  
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.00View SEC Filing  
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.20View SEC Filing  
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cesca Therapeutics (NASDAQ:KOOL)
Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
Source:
DateHeadline
finance.yahoo.com logoCesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 11:15 AM
finance.yahoo.com logoCesca Therapeutics to Present at the Inaugural Cell and Gene Exchange 2017
finance.yahoo.com - May 18 at 9:01 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 12 at 1:38 PM
reuters.com logoBRIEF-Cesca Therapeutics Q3 loss per share $0.21
www.reuters.com - May 11 at 11:41 PM
seekingalpha.com logoCesca Therapeutics (KOOL) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 11:41 PM
finance.yahoo.com logoInvestor Network: Cesca Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 6:40 PM
finance.yahoo.com logoCesca Therapeutics Announces Fiscal Third Quarter and Nine Month 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - May 11 at 6:40 PM
finance.yahoo.com logoCesca Therapeutics to Announce Fiscal Third Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - May 4 at 6:20 PM
americanbankingnews.com logoCesca Therapeutics (KOOL) Earning Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:00 PM
finance.yahoo.com logoCesca to Exhibit at the 25th International Society for Cellular Therapy (ISCT) Annual Meeting
finance.yahoo.com - May 2 at 4:36 PM
americanbankingnews.com logoCesca Therapeutics (KOOL) Receives Daily Coverage Optimism Score of -0.25
www.americanbankingnews.com - April 23 at 9:05 AM
americanbankingnews.com logoCesca Therapeutics (KOOL) Receives News Sentiment Score of 0.05
www.americanbankingnews.com - April 20 at 11:49 PM
finance.yahoo.com logoCESCA Therapeutics to Present at the 2017 International ... - Yahoo Finance
finance.yahoo.com - April 11 at 10:58 PM
feeds.benzinga.com logoCESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair
feeds.benzinga.com - April 11 at 8:21 AM
americanbankingnews.com logoZacks: Brokerages Expect Cesca Therapeutics Inc (KOOL) Will Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 9 at 8:14 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Short Interest Update
www.americanbankingnews.com - April 8 at 11:08 AM
finance.yahoo.com logoCesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International Precision Medicine Summit
finance.yahoo.com - April 7 at 6:12 PM
finance.yahoo.com logoCesca Therapeutics Announces Senior Management Promotions
finance.yahoo.com - April 4 at 6:31 AM
americanbankingnews.com logoCesca Therapeutics Inc (KOOL) Given Hold Rating at Maxim Group
www.americanbankingnews.com - March 21 at 3:40 PM
streetinsider.com logoCesca Therapeutics (KOOL) Announces CLI Feasibility Study Published in Stem Cells International - StreetInsider.com
www.streetinsider.com - March 21 at 12:07 PM
us.rd.yahoo.com logoCesca CLI Feasibility Study Published in Peer-Reviewed Journal
us.rd.yahoo.com - March 20 at 10:42 AM
bizjournals.com logoLocal medical technology company reports positive results from clinical trial
www.bizjournals.com - March 16 at 6:59 PM
finance.yahoo.com logoBlog Coverage Cesca Therapeutics Announces Encouraging Results from a Study of its Treatment of Chronic Non-healing Ulcers
finance.yahoo.com - March 16 at 6:59 PM
finance.yahoo.com logoWednesday's Biggest Biopharma Movers - Yahoo Finance
finance.yahoo.com - March 16 at 4:30 AM
nasdaq.com logoHealth Care Sector Update for 03/15/2017: KOOL,CPRX,CXRX - Nasdaq
www.nasdaq.com - March 15 at 11:28 PM
finance.yahoo.com logoCesca Therapeutics Announces Closing of $5 Million Revolving Line of Credit - Yahoo Finance
finance.yahoo.com - March 15 at 11:28 PM
streetinsider.com logoCesca Therapeutics (KOOL) Releases Positive Data on PRP for Treatment of Chronic Non-Healing Ulcers - StreetInsider.com
www.streetinsider.com - March 15 at 11:28 PM
streetinsider.com logoCesca Therapeutics (KOOL) Releases Positive Data on PRP for Treatment of Chronic Non-Healing Ulcers
www.streetinsider.com - March 15 at 6:26 PM
us.rd.yahoo.com logo6:00 am Cesca Therapeutics announces 'encouraging' data from a study evaluating the use of autologous platelet rich plasma for the treatment of chronic non-healing ulcers
us.rd.yahoo.com - March 15 at 6:26 PM
us.rd.yahoo.com logoCesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers
us.rd.yahoo.com - March 15 at 6:26 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
biz.yahoo.com - March 10 at 7:26 PM
seekingalpha.com logoIs Caladrius Biosciences Inc. A Buy?
seekingalpha.com - March 10 at 2:08 AM
globenewswire.com logoCesca Therapeutics Strengthens Leadership Team and Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 2 at 10:28 AM
bizjournals.com logoEXCLUSIVE: Medical technology company raises $500,000
www.bizjournals.com - February 28 at 6:21 PM
finance.yahoo.com logoCESCA THERAPEUTICS INC. Financials
finance.yahoo.com - February 17 at 4:22 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits
biz.yahoo.com - February 17 at 4:22 PM
baystreet.ca logoCesca Therapeutics (KOOL) Falls on Q2 Loss
www.baystreet.ca - February 14 at 7:38 PM
finance.yahoo.com logoCesca Therapeutics Reports Second Quarter Fiscal 2017 Financial Results and Provides Business Update
finance.yahoo.com - February 13 at 7:16 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - February 13 at 7:16 PM
biz.yahoo.com logoQ2 2017 Cesca Therapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - February 13 at 10:46 AM
bizjournals.com logoSacramento medical equipment developer raises $500,000 in most recent financing round
www.bizjournals.com - January 24 at 6:55 PM
finance.yahoo.com logoCesca Therapeutics Appoints Dr. Joseph Thomis to Its Board of Directors
finance.yahoo.com - January 17 at 12:07 PM
streetinsider.com logoCesca Therapeutics (KOOL) IDE Supplement for Phase III Clinical Trial Approved by FDA - StreetInsider.com
www.streetinsider.com - January 6 at 12:33 AM
streetinsider.com logoCesca Therapeutics (KOOL) IDE Supplement for Phase III Clinical Trial Approved by FDA
www.streetinsider.com - January 5 at 7:31 PM
finance.yahoo.com logo6:05 am Cesca Therapeutics receives FDA approval for significant revisions to its pivotal study for treatment of Critical Limb Ischemia
finance.yahoo.com - January 5 at 7:30 PM
globenewswire.com logoCesca Therapeutics to Present at the 9th Annual Biotech Showcase ... - GlobeNewswire (press release)
globenewswire.com - January 3 at 9:46 PM
finance.yahoo.com logoCesca Therapeutics to Present at the 9th Annual Biotech Showcase
finance.yahoo.com - January 3 at 11:17 AM
247wallst.com logoInsiders Keep Buying as Market Wraps on 2016: Tronic, Six Flags, Virtu Financial, Cesca Therapeutics and More - 24/7 Wall St.
247wallst.com - January 2 at 10:04 AM
rttnews.com logoCesca Therapeutics Inc. (KOOL) Is Surging In Early Trade
www.rttnews.com - December 29 at 6:14 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
biz.yahoo.com - December 21 at 6:23 AM

Social

Chart

Cesca Therapeutics (KOOL) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff